Cambrex is expanding its mid-scale and large-scale API manufacturing capacity in Charles City, Iowa. The $50+ million investment aims to meet growing demand for small molecule drug substance development and manufacturing. It will be the sixth major investment that Cambrex has made at the site in the past eight years to support customers in mid-scale, large-scale and highly potent small molecule API manufacturing. The expansion, which will be operational in early 2022, will add three large-sc...